Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul B Keiser

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
The American Journal of Tropical Medicine and Hygiene|November 25, 2003
Clinical characteristics of post-treatment reactions to ivermectin/albendazole for Wuchereria bancrofti in a region co-endemic for Mansonella perstansPaul B Keiser, Yaya I Coulibaly, Falaye Keita, et al.
Infection and Immunity|July 25, 2006
Filaria-induced monocyte dysfunction and its reversal following treatmentRoshanak Tolouei Semnani, Paul B Keiser, Yaya I Coulibaly, et al.
Vaccine|July 24, 2010
Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccineWendell D Zollinger, Mikhail A Donets, Deborah H Schmiel, et al.
The American Journal of Tropical Medicine and Hygiene|April 29, 2020
Safety and Immunogenicity of an AS03<sub>B</sub>-Adjuvanted Inactivated Tetravalent Dengue Virus Vaccine Administered on Varying Schedules to Healthy U.S. Adults: A Phase 1/2 Randomized StudyLeyi Lin, Kirsten E Lyke, Michael Koren, et al.
Vaccine|July 27, 2011
Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccineMark S Riddle, Robert W Kaminski, Carlos Williams, et al.
The Journal of Infectious Diseases|September 23, 2020
Immunogenicity of a Live-Attenuated Dengue Vaccine Using a Heterologous Prime-Boost Strategy in a Phase 1 Randomized Clinical TrialLeyi Lin, Michael A Koren, Kristopher M Paolino, et al.
The Lancet. Infectious Diseases|June 30, 2023
Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trialMichael A Koren, Leyi Lin, Kenneth H Eckels, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
The American Journal of Tropical Medicine and Hygiene|November 25, 2003
Clinical characteristics of post-treatment reactions to ivermectin/albendazole for Wuchereria bancrofti in a region co-endemic for Mansonella perstansPaul B Keiser, Yaya I Coulibaly, Falaye Keita, et al.
Infection and Immunity|July 25, 2006
Filaria-induced monocyte dysfunction and its reversal following treatmentRoshanak Tolouei Semnani, Paul B Keiser, Yaya I Coulibaly, et al.
Vaccine|July 24, 2010
Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccineWendell D Zollinger, Mikhail A Donets, Deborah H Schmiel, et al.
The American Journal of Tropical Medicine and Hygiene|April 29, 2020
Safety and Immunogenicity of an AS03<sub>B</sub>-Adjuvanted Inactivated Tetravalent Dengue Virus Vaccine Administered on Varying Schedules to Healthy U.S. Adults: A Phase 1/2 Randomized StudyLeyi Lin, Kirsten E Lyke, Michael Koren, et al.
Vaccine|July 27, 2011
Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccineMark S Riddle, Robert W Kaminski, Carlos Williams, et al.
The Journal of Infectious Diseases|September 23, 2020
Immunogenicity of a Live-Attenuated Dengue Vaccine Using a Heterologous Prime-Boost Strategy in a Phase 1 Randomized Clinical TrialLeyi Lin, Michael A Koren, Kristopher M Paolino, et al.
The Lancet. Infectious Diseases|June 30, 2023
Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trialMichael A Koren, Leyi Lin, Kenneth H Eckels, et al.
Pageof 3